PharmiWeb Recruiter Blog

• Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.
• Aspect to receive 75 million US dollars in initial payments and up to 650 million dollars in future milestone payments per product arising from the collaboration, plus tiered royalties.

Vancouver, BC, Canada and Bagsværd, Denmark, 12 April 2023 – Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.

RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list for the second time in the past three years. The company also made the list in 2021.

• Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.
• Aviceda Executives will participate in a Cancer Showcase Event as part of the 25th Anniversary of the Good Friday Agreement Conference at Queen’s to highlight Northern Ireland’s emerging global reputation in the translational oncology ecosystem.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). Aviceda’s HALOS™ (High-Affinity Ligands of Sigelcs) nanotechnology platform, based on an invention from the research team led by Professor Chris Scott, Scientific Co-Founder and Chief Scientific Officer of Aviceda & Interim Dean of Research, Faculty of Medicine, Health, and Life Sciences, at Queen’s, harnesses the power of glycobiology to modulate the innate immune system to develop next-generation breakthrough therapeutics, with a focus on immuno-oncology.

Company Recognized for Positive Vaccine Expertise Contributions

MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health^® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for Best Contract Research Organization (CRO). Presented at the 2023 World Vaccine Congress in Washington, D.C., the award recognizes the vaccine industry’s most outstanding efforts, accomplishments and positive contributions of companies and individuals.

RAHWAY, N.J.-–(3BL MEDIA)-– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the third consecutive year, ranking No. 1 in the pharmaceutical industry and advancing 38 spots in the overall rankings from last year—from No. 67 overall in 2022 to No. 29 overall in 2023.   

Partnership will distribute screening kits to communities at higher risk of colon cancer

New, independent kidney health technology company will combine expertise from two industry leaders to drive care transformation

• Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations
• Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy

DUBLIN, March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.

Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences

MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health^® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to drive smarter and more effective scientific exchange. This integrated program seeks to ensure customers, and the clinicians they serve, have access to the latest education to optimize patient outcomes.

WALTHAM, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus.